However dose of surfactant, number of doses, dose intervals, type of surfactant, and techniques of administration has still been under investigation.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Respiratory distress syndrome (RDS) and its complications are major causes of mortality and morbidity among newborns.
📊
Key Findings & Data:Besides developments in supportive treatment and use of assisted mechanical ventilation, application of surfactant replacement treatment has significantly recently decreased RDS related mortality.
💡
Conclusion & Impact:However dose of surfactant, number of doses, dose intervals, type of surfactant, and techniques of administration has still been under investigation.
Respiratory distress syndrome (RDS) and its complications are major causes of mortality and morbidity among newborns. One-fourth of newborn deaths is due to RDS in well developed countries. Besides developments in supportive treatment and use of assisted mechanical ventilation, application of surfactant replacement treatment has significantly recently decreased RDS related mortality. Fujiwara and colleagues pioneered surfactant treatment in 1980 and numerous clinical trials has been performed since then. However dose of surfactant, number of doses, dose intervals, type of surfactant, and techniques of administration has still been under investigation.
Kültürsay, N., Tansuğ, N. (2000). Surfactant and Use of Exogenous Surfactant in Neonatal RDS. Meandros Medical And Dental Journal, Volume: 1 Issue: 2. https://ajindex.com/articles/1291497
Mercier CE, Soll RF. Clinical trials of natural surfactant in respiratory distress syndrome. Clin Perinatol 1993; 20: 711-35.
Corbet A. Clinical trials of synthetic surfactant in respiratory distress syndrome of premature infants. Clin Perinatol 1993; 20: 737-60.
Fanaroff AA, Martin RJ. The respiratory distress syndrome and its manegement. In: Neonatal-Perinatal Medicine. Diseases of The Fetus and Infant. Ed. Fanaroff AA, Martin RJ. Fifth Edition, Msby Year Book, St Louis, Missouri, 1992: 810-20.
Neonatal Resüsitasyon Programý 2000. T.C: Saðlýk Bakanlýðý Ana Çocuk Saðlýðý ve Aile Planlamasý Genel Müdürlüðü.
Hansen T, Corbet A. Lung Development and Function. In: Averys Diseases of The Newborn. Ed. Taeusch HW, Ballard RA, Seventh Edition, WB Saunders Company, Philadelpia. 1998: 541-51.
Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene responsible for neonatal respiratory disease in multible kindreds. J Clin Invest 1994; 93: 1860-3.
Adams FH, Fujiwara T, Emmanouilides GC, et al: Lung phospholipid of the human fetus and infants with and without hyaline membrane disease. J Pediatr 1970; 77: 833-7.
Hallman M, Merritt TA, Pohjavuori M, et al. Surfactant substitution on lung effluent phospholipids in respiratory distress syndrome: Evaluation of surfactant phospholipid turnover, pool size, and the relationship to severity of respiratory failure. Pediatr Res 1986; 20:1228-34.
Jackson JC, Palmer S, Standaert TA, et al. Devolepmental changes of surface active material in newborn non-human primates. Am Rev Dis 1984; 29: 204-9.
Jobe AH. Fetal lung development, tests for maturation, induction of maturation and treatment In: Maternal Fetal Medicine Eds: Creasy RK, Resnik RWB. Saunders Company Philadelphia, 1989, 423-40.
Whitsett JA, Pryhuber GS, Rice WR, et al. Acute respiratory disorders. In: Neonatology Pathophysiolgy and Management of the Newborn. Ed. Avery GB, Fourth Edition, JB Lippincott Company, Philadelphia. 1994: 429-52.
Schürch S. Surface Tension Properties of Surfactant. Clin Perinatol 1993; 20: 669-82.
Couser RJ, Ferrara TB, Ebert J, et al. Effects of exogenous surfactant therapy on dynamic compliance during mechanical breathing in preterm infants with hyaline membrane disease. J Pediatr 1990: 116: 119-24.
Fujiwara T, Maeta H, Chida S, et al. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980; 1: 55-9.
OSÝRÝS Early versus delayed neonatal administration of a synthetic surfactant- the judgement of OSIRIS. Lancet 1992; 340: 1363-9.
Kendig JW, Ryan RM, Sinkin RA, et al. Comparison of Two Strategies for Surfactant Prophylaxis in Very Prematüre Infants: A Multicenter Randomized Trial. Pediatrics 1998; 101: 1006-12.
Hudak ML, Martin DJ, Egan EA, et al. A Multicenter Randomized Masked Comparison Trial of Synthetic Surfactant Versus Calf Lung Surfactant Extract in the Prevention of Neonatal Respiratory Distress Syndrome. Pediatrics 1997; 100: 39-50.
Vermont- Oxford Neonatal Network. A Multicenter, Randomized Trial Comparing Synthetic Surfactant With Modified Bovine Surfactant Extract in the Treatment of Neonatal Respiratory Distress Syndrome. Pediatrics 1998; 97: 1-6.
Soll Rf. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. In: Cochrane Library, Issue 1, 2000. Oxford: Update Sortware.
American Academy of Pediatrics. Committee on Fetus and Newborn. Pediatrics 1999; 103: 684-5.
Murdoch E, Kempley ST. Randomized trial examining cerabral haemodynamics following artificial or animal surfactant. Acta Paediatr 1998; 87: 411-5.
Long W, Corbet A, Alien A, et al. Retrospective search for bleeding diathesis among premature newborn infants with pulmonary hemorrhage after surfactant treatment. J Pediatr 1992; 120: 45-8.
Pappin A, Shenker N, Hack M, et al. Extensive intraalveolar pulmoner homorrhage in infants dying after surfactant therapy. J Pediatr 1994; 124: 621-6.
Whitsett JA, Hull WM, Luse S. Failure to detect surfactant protein-spesific antibodies in sera of premature infants treated with Survanta, a modified bovine surfactant. Pediatrics 1991; 87: 505-10.
Kendig JW, Ryan RM, Sinkin RA, et al. Comparison of Two Strategies for Surfactant Prophylaxis in Very Prematüre Infants: A Multicenter Randomized Trial. Pediatrics 1998; 101: 1006-12.